CA2918052A1 - Elucidation of ion exchange chromatography input optimization - Google Patents

Elucidation of ion exchange chromatography input optimization Download PDF

Info

Publication number
CA2918052A1
CA2918052A1 CA2918052A CA2918052A CA2918052A1 CA 2918052 A1 CA2918052 A1 CA 2918052A1 CA 2918052 A CA2918052 A CA 2918052A CA 2918052 A CA2918052 A CA 2918052A CA 2918052 A1 CA2918052 A1 CA 2918052A1
Authority
CA
Canada
Prior art keywords
polypeptide
antibody
buffer
contaminants
chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2918052A
Other languages
English (en)
French (fr)
Inventor
Daniel Mcdonald
Thomas W. Patapoff
Yajun Jennifer Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2918052A1 publication Critical patent/CA2918052A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8658—Optimising operation parameters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Confectionery (AREA)
CA2918052A 2013-07-12 2014-07-11 Elucidation of ion exchange chromatography input optimization Abandoned CA2918052A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845890P 2013-07-12 2013-07-12
US61/845,890 2013-07-12
PCT/US2014/046338 WO2015006686A1 (en) 2013-07-12 2014-07-11 Elucidation of ion exchange chromatography input optimization

Publications (1)

Publication Number Publication Date
CA2918052A1 true CA2918052A1 (en) 2015-01-15

Family

ID=51257626

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2918052A Abandoned CA2918052A1 (en) 2013-07-12 2014-07-11 Elucidation of ion exchange chromatography input optimization

Country Status (18)

Country Link
US (2) US10274466B2 (https=)
EP (2) EP3019516B1 (https=)
JP (2) JP6462681B2 (https=)
KR (1) KR102251127B1 (https=)
CN (1) CN105377873B (https=)
AU (1) AU2014287044B2 (https=)
BR (1) BR112016000231A8 (https=)
CA (1) CA2918052A1 (https=)
ES (1) ES2705700T3 (https=)
HR (1) HRP20190071T1 (https=)
IL (1) IL243305B (https=)
MX (1) MX368107B (https=)
PL (1) PL3019516T3 (https=)
RU (1) RU2016104542A (https=)
SG (1) SG11201600221YA (https=)
SI (1) SI3019516T1 (https=)
TR (1) TR201818966T4 (https=)
WO (1) WO2015006686A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014287044B2 (en) 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
US11460455B2 (en) 2014-11-12 2022-10-04 Cytiva Sweden Ab Method and system for determining the influence of experimental parameters on a liquid chromatography protocol
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
AU2019246983B2 (en) * 2018-04-02 2025-12-18 Amgen Inc. Erenumab compositions and uses thereof
WO2020010304A2 (en) * 2018-07-05 2020-01-09 Ovation Diagnostics Llc BCl-2 Antibodies and Immunoassay for Diagnosis of Cancer
KR20200080748A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
WO2024261724A1 (en) * 2023-06-23 2024-12-26 Lupin Limited Ion-exchange chromatography for separation and analysis of charge variants

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666855A (en) * 1985-07-31 1987-05-19 Massachusetts Institute Of Technology Rapid method for determining the isoelectric point for amphoteric molecules
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0287513B1 (en) 1987-04-11 1992-12-02 Ciba-Geigy Ag An isoelectric focusing process and a means for carrying out said process
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
SE9803838D0 (sv) 1998-11-09 1998-11-09 Knut Irgum A chromatography method and a column material useful in said method
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
EP1628729A2 (en) * 2003-05-16 2006-03-01 Cryobiophysica, Inc. External gradient chromatofocusing
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
US7906630B2 (en) 2004-04-27 2011-03-15 PerkinElmer Heath Sciences, Inc. Method for identifying peptides in a biological sample
JP5008564B2 (ja) 2004-05-20 2012-08-22 ウオーターズ・テクノロジーズ・コーポレイシヨン 混合物中のタンパク質を同定する方法および装置
CA2583081A1 (en) 2004-06-16 2006-01-19 Bio-Rad Laboratories, Inc. Multichemistry fractionation
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JP2006087394A (ja) 2004-09-27 2006-04-06 Wako Pure Chem Ind Ltd 核酸抽出方法および核酸抽出キット
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
JP2010089001A (ja) 2008-10-07 2010-04-22 Japan Organo Co Ltd クロマト分離方法
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
SG178078A1 (en) 2009-07-24 2012-03-29 Hoffmann La Roche Optimizing the production of antibodies
JP5787891B2 (ja) * 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
CN102958602A (zh) 2010-07-09 2013-03-06 通用电气健康护理生物科学股份公司 层析方法及为此使用的介质
TW201235799A (en) 2011-01-24 2012-09-01 Sharp Kk Exposure apparatus, liquid crystal display device and method for manufacturing same
EA201391421A1 (ru) 2011-03-31 2014-02-28 Апотекс Текнолоджиз Инк. Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
CN105051528A (zh) * 2012-11-15 2015-11-11 弗·哈夫曼-拉罗切有限公司 离子强度介导的pH梯度离子交换色谱
AU2014287044B2 (en) 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization

Also Published As

Publication number Publication date
WO2015006686A1 (en) 2015-01-15
SG11201600221YA (en) 2016-02-26
CN105377873A (zh) 2016-03-02
JP2019090818A (ja) 2019-06-13
HRP20190071T1 (hr) 2019-02-22
AU2014287044B2 (en) 2020-02-06
HK1222183A1 (zh) 2017-06-23
EP3019516A1 (en) 2016-05-18
US20190310234A1 (en) 2019-10-10
JP6462681B2 (ja) 2019-01-30
CN105377873B (zh) 2021-03-30
IL243305B (en) 2019-09-26
ES2705700T3 (es) 2019-03-26
BR112016000231A8 (pt) 2019-12-31
JP2016529489A (ja) 2016-09-23
PL3019516T3 (pl) 2019-04-30
AU2014287044A1 (en) 2016-02-11
KR20160030251A (ko) 2016-03-16
EP3019516B1 (en) 2018-11-14
IL243305A0 (en) 2016-03-31
US10921297B2 (en) 2021-02-16
RU2016104542A (ru) 2017-08-17
MX368107B (es) 2019-09-18
US10274466B2 (en) 2019-04-30
WO2015006686A8 (en) 2018-10-04
EP3536699A1 (en) 2019-09-11
US20160161455A1 (en) 2016-06-09
MX2016000181A (es) 2016-03-09
TR201818966T4 (tr) 2019-01-21
KR102251127B1 (ko) 2021-05-11
SI3019516T1 (sl) 2019-02-28

Similar Documents

Publication Publication Date Title
US10712322B2 (en) Ionic strength-mediated pH gradient ion exchange chromatography
AU2022291517B2 (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
US10940401B2 (en) Method for chromatography reuse
US10921297B2 (en) Elucidation of ion exchange chromatography input optimization
CA3033737C (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
HK1222183B (zh) 阐明离子交换层析输入优化

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190703

FZDE Discontinued

Effective date: 20231219